Savara Inc Sustainability Reports
Savara Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare respiratory diseases. Its lead product candidate is MOLBREEVI, an inhaled treatment in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 5493002JO0WM3YMJXG33
FIGI: BBG001SFTVM9
1 reports from 2021 to 2021